BLSM

Conviction 0HealthcareScan · Fri, Oct 2, 2026

BlossomHill Therapeutics, Inc. (BLSM) closed at $19.71 (+6.02%) on Oct 2, 2026. RSI(14) 46, -26.5% from its 52-week high, +23.2% year to date. Sector: Healthcare · Biotechnology.

BLSM$19.71+6.02%

ResistanceSupportVol 14Insider buy

Vol MA14 261.03K

Aug 7Aug 19Aug 31Sep 10Sep 22Oct 2

BlossomHill Therapeutics, Inc.Biotechnology

Price19.71

Change+6.02%

Gap+0.11%

Rel volume0.46×

Avg volume237.54K

Avg $ vol5.44M

SMA 2022.31

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 25.27

RSI (14)46

MACD hist-0.77

MACD cross—

Stoch %K / %D14 / 6

ADX (14)26

+DI / −DI20 / 24

RSI divergence—

MACD divergence—

ATR %9.84%

ADR %9.76%

52w high26.82

52w low15.80

From 52w high-26.51%

Above 52w low+24.75%

New 52w highNo

SqueezeOff

Bollinger width44.98%

%B0.24

Donchian pos13.57%

Donchian high27.99

Donchian low18.41

AVWAP (52w high)21.98

vs AVWAP high-10.32%

AVWAP (52w low)19.50

vs AVWAP low+1.08%

OBV trendFlat

Chaikin MF (20)-0.22

Today vs 20d0.46×

Avg vol (14d)261.03K

Avg vol (20d)237.54K

Avg $ vol (20d)5.44M

Market cap626.48M

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank51.6

1 week-0.20%

1 month+1.70%

3 months—

6 months—

1 year—

YTD+23.19%

P/E—

P/B-3.58

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current5.42

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target35.40

Target upside79.60%

Analyst ratingBuy

Institutional—

Ent. value531.1M

Revenue—

Net income-23.76M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float17.74M

Float %55.8%

Short interest110.78K

Days to cover0.7d

Short volume75.4%

Squeeze score25 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$8.75 vs −$0.84

Last surprise-941.7% miss

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank51.6 / 100

Group rank14 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance25.68

Support16.59

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BLSM

All disclosures →

No recent disclosed trades by Congress in BLSM. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BLSM · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
GORDON CARL L Director · Common Stock · 2026-08-10	Convert	1.04M	—	2026-08-10	2026-08-12
GORDON CARL L Director · Common Stock · 2026-08-10	Convert	1.05M	—	2026-08-10	2026-08-12
GORDON CARL L Director · Common Stock · 2026-08-10	Buy	625K	$10M	2026-08-10	2026-08-12
GORDON CARL L Director · Series A Preferred Stock · 2026-08-10	Convert	1.04M	—	2026-08-10	2026-08-12
GORDON CARL L Director · Series B Preferred Stock · 2026-08-10	Convert	1.05M	—	2026-08-10	2026-08-12
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-10	Convert	1.05M	—	2026-08-10	2026-08-12
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-10	Buy	625K	$10M	2026-08-10	2026-08-12
ORBIMED ADVISORS LLC Director · Series A Preferred Stock · 2026-08-10	Convert	1.04M	—	2026-08-10	2026-08-12
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-10	Convert	1.04M	—	2026-08-10	2026-08-12
ORBIMED ADVISORS LLC Director · Series B Preferred Stock · 2026-08-10	Convert	1.05M	—	2026-08-10	2026-08-12

SEC filings

EDGAR filings in BLSM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

BLSM

Recent news

Get daily signals & real-time alerts.